Not Yet RecruitingPhase 1

A Study to See How Safe a New Medicine (NNC6022-0004) is in Healthy People and People Living With Obesity

Netherlands128 participantsStarted 2026-07-06

Plain-language summary

This study is being done to look at the efficacy single and multiple ascending dose study investigating safety, tolerability, pharmacokinetics, food effect and target engagement in healthy adults including a single cohort in adults living with obesity. Participants will either get NNC6022-0004, (the treatment being tested) or Placebo (a treatment that has no active medicine in it) and which treatment participants get is decided by chance.

Who can participate

Age range

18 Years – 65 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

For Parts A, B, C and D: Body mass index (BMI) between 18.5 to 29.9 kilogram per meter square (kg/m\^2) (both inclusive) at screening.

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Part A: Area under the NNC6022-0001 plasma concentration-time curve from time 0 to last measurable plasma concentration (AUC0-tz) after a single dose

Timeframe: From pre-dose (Day 1) until visit 3 (Day 9)

Part A: Maximum observed plasma concentration (Cmax) of NNC6022-0001 after a single dose

Timeframe: From pre-dose (Day 1) until visit 3 (Day 9)

Part B: Number of treatment emergent adverse events (TEAE)

Timeframe: From time of dosing (Day 1) to end of study visit (Day 14)

Part C: Number of treatment emergent adverse events

Timeframe: From time of dosing (Day 1) to end of study visit (Day 41)

Part D: Area under the NNC6022-0001 plasma concentration-time curve from time 0 to last measurable plasma concentration (AUC0-tz) after a single dose

Timeframe: From pre-dose (Day 1 or Day 8) to end of visit (Day 5 or Day 12)

Part E: Number of treatment emergent adverse events

Timeframe: From time of dosing (Day 1) to end of study visit (Day 13)

Trial details

NCT IDNCT07693868

SponsorNovo Nordisk A/S

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2027-08-01

Contact for this trial

Novo Nordisk

(+1) 866-867-7178 clinicaltrials@novonordisk.com

View on ClinicalTrials.gov More Obesity trials

Plain-language summary

Who can participate

Age range

18 Years – 65 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

For Parts A, B, C and D: Body mass index (BMI) between 18.5 to 29.9 kilogram per meter square (kg/m\^2) (both inclusive) at screening.

What they're measuring

Part A: Area under the NNC6022-0001 plasma concentration-time curve from time 0 to last measurable plasma concentration (AUC0-tz) after a single dose

Timeframe: From pre-dose (Day 1) until visit 3 (Day 9)

Part A: Maximum observed plasma concentration (Cmax) of NNC6022-0001 after a single dose

Timeframe: From pre-dose (Day 1) until visit 3 (Day 9)

Part B: Number of treatment emergent adverse events (TEAE)

Timeframe: From time of dosing (Day 1) to end of study visit (Day 14)

Part C: Number of treatment emergent adverse events

Timeframe: From time of dosing (Day 1) to end of study visit (Day 41)

Part D: Area under the NNC6022-0001 plasma concentration-time curve from time 0 to last measurable plasma concentration (AUC0-tz) after a single dose

Timeframe: From pre-dose (Day 1 or Day 8) to end of visit (Day 5 or Day 12)

Part E: Number of treatment emergent adverse events

Timeframe: From time of dosing (Day 1) to end of study visit (Day 13)